Latest news with #SAST
Deccan Herald
6 hours ago
- Health
- Deccan Herald
SAST helpline to attend Covid calls too
Well-placed sources in the department on Wednesday confirmed that the SAST helpline 1800-425-8330 will be directed to receive Covid-related calls. This comes after Chief Minister Siddaramaiah on Monday said that a Covid helpline would be set up to support the public.
The Hindu
12 hours ago
- Health
- The Hindu
Utilisation of oncology procedures under AB-ArK see over a six-fold rise in last six years
Utilisation of oncology procedures under the Ayushman Bharat Arogya Karnataka (AB-ArK) has seen over a six-fold rise in the last six years. From 9,328 pre-authorisations approved under the flagship health scheme in 2018-2019, the number has shot up to 60,301 in 2024-2025, according to data from the Health Department. Karnataka has a high cancer burden with around one lakh new cases reported every year. The State has an estimated cancer prevalence of around 2.35 lakh cases, according to the Population Based Cancer Registry at the State-run Kidwai Memorial Institute of Oncology in Bengaluru. The cumulative risk for developing cancer in their lifetime is one in seven for men and one in six for women in Karnataka, according to doctors.. The State is providing tertiary care for oncology procedures under the health scheme and a total of 109 hospitals, including 96 private hospitals, are empanelled under Suvarna Arogya Suraksha Trust (SAST), the nodal agency that is implementing AB-ArK. As many as eight government medical colleges and 22 private medical colleges are also empanelled for oncology specialty under SAST. However, empanelled hospitals for oncology are present only in 21 districts and people from Bidar, Yadgiri, Vijayanagara Koppal, Chitradurga, Chickballapura, Ramanagara, Kodagu, Chamarajanagar and Chikkamagaluru have to travel to other districts for cancer treatment. Pre-authorisations A total of 2.61 lakh pre-authorisations have been approved under the scheme for an amount of ₹1,301.92 crore from 2018-2019 when the scheme was launched. In 2024-2025, a total of 60,301 pre-authorisations for an amount of ₹271.72 crore have been expended under the scheme. Among the procedures covered under the scheme, 56% are medical oncology procedures (chemotherapy), 25% are radiation oncology procedures and 19% surgical oncology cases, according to data. Apart from Kidwai, Mysuru Medical College and Research Institute, VTSM Peripheral Cancer Centre in Kalaburgi, Karnataka Institute of Medical Sciences in Hubballi and Vijaynagar Institute of Medical Sciences in Ballari are the top five public health facilities with highest utilisation of oncology procedures. Since 2022-2023, in the category of government hospitals, Kidwai institute has done the highest procedures under the scheme (51,418). Among private empanelled hospitals, Bharat Hospital and Institute of Oncology in Mysuru has done the highest procedures at 6,204, according to data. Female cancers high in Bengaluru In Bengaluru, of the estimated 15,603 cases registered annually, 8,723 are female cancers. Of the 6,880 male cancers reported, lung cancer continues to be the most predominant site (9.7% of the total male cancers). Lung cancer is followed by cancers of the prostate (6.9%), stomach (6.5%), and mouth (6.4%). Among females, breast cancer is the most common constituting 31.5% of the total female cancers followed by cancer of the cervix (9.1%), ovary (6.4%), mouth (4.3%), and corpus uteri (4.2%), according to data.
Zawya
2 days ago
- Business
- Zawya
Navigating AI and PoPIA: Juta hosts expert webinar on ethical AI use in South Africa
Artificial intelligence (AI) is reshaping industries, but how does it align with South Africa's Protection of Personal Information Act (PoPIA)? Join leading experts as we explore how PoPIA compliance can support the responsible and ethical use of AI. We'll examine AI governance, data protection, and global regulatory developments, including the EU AI Act and South Africa's National AI Policy Framework. Expect key insights on what PoPIA compliance means in the AI era, information officers' responsibilities, and updates from the information regulator, including enforcement actions and guidance notes. Date: 10 June 2025 Time: 3pm – 5pm (SAST) Platform: Zoom webinar Your fee: R700 incl. VAT. Book 10 or more delegates and qualify for a corporate discount. Contact seminars@ for more information. Who should attend? - Information officers and compliance professionals - Data protection officers and legal advisors - IT and risk managers overseeing AI and data security - Business leaders navigating AI governance - Privacy and security consultants Webinar topics: - Global trends in AI, data protection, and privacy laws - Regulatory developments, including the EU AI Act and SA's AI Policy Framework - The intersection of AI governance and PoPIA compliance - Information officer's role in AI-driven compliance strategies - Latest updates from the information regulator, including enforcement notices and guidance notes Included in your registration fee: - Two-week free trial access to Juta's PoPIA Portal - Six-month subscription to Legalbrief eLaw - One-month subscription to Contractzone PoPIA Library Register now. Ilze Luttig Hattingh – Novation Consulting Ilze is a regulatory compliance attorney with expertise in risk management and legal clarity. She holds a LLB from Stellenbosch University and co-authored Over-thinking the Protection of Personal Information Act. She is currently working toward the IAPP AI Governance Professional certification. Sarah Buerger – Novation Consulting Sarah is a legal consultant with expertise in intellectual property, mergers and acquisitions, and data protection. She holds a Master's in Intellectual Property Law and a Bachelor of Social Science in Psychology and Law. Her experience includes advising on contract negotiations, promotional compliance, and privacy law. Johann Steyn – AI for Business Johann is a human-centred AI advocate and thought leader. A prolific writer, speaker, and educator, he helps organisations understand and implement AI technologies responsibly. He is a working group member contributing to South Africa's national AI strategy development. Nerushka Bowan – AI author and founder of the LITT Institute Nerushka is a pioneer in AI law and legal innovation, helping professionals navigate emerging technologies responsibly. She is the founder of the LITT Institute, leading initiatives such as the #GenAI Legal Accelerator and Legal Innovation Accelerator courses. Host of the Brains, Bubbly & Beyond podcast, Nerushka is also the author of Generative AI for the Future-Ready Lawyer (Juta, 2025). Don't miss this essential webinar to stay ahead of AI regulations, understand your compliance responsibilities, and gain practical insights from industry experts. Contact us: Paula Whitaker 083 259 3452 or +27(21) 659 2408.
Mint
3 days ago
- Business
- Mint
Nestle India share price edges higher as LIC raises stake in the packaged foods company
Shares of Nestle India gained over 2 percent in intra-day trade on Monday, May 26, following an announcement from Life Insurance Corporation of India (LIC) regarding an increase in its stake in the packaged foods major. The stake hike, which pushed LIC's shareholding above the regulatory threshold of 5 percent, sparked renewed investor interest in the stock. The development comes amid broader news around Nestle's global investment plans and a mixed set of quarterly earnings. In a regulatory filing submitted under SEBI's Substantial Acquisition of Shares and Takeovers (SAST) Regulations, LIC disclosed that it had acquired 1,49,000 additional shares of Nestle India through a market purchase on May 23, 2025. With this transaction, LIC's total holding rose to 4,82,24,710 shares, representing 5.001 percent of the company's equity capital. Before this acquisition, LIC held 4,80,75,710 shares or 4.986 percent of the company's total equity. The crossing of the 5 percent ownership threshold triggered the mandatory disclosure requirement. Nestle India's total share capital stood unchanged at ₹ 96.41 crore. Following the announcement, Nestle India's stock rose as much as 2.1 percent during the trading session to hit a day's high of ₹ 2,464.50. Despite the uptick, the stock remains about 11 percent below its 52-week high of ₹ 2,777, which was recorded in September 2024. It had touched its 52-week low of ₹ 2,115 in March 2025. The FMCG stock has seen a volatile run over the past few months. After shedding 5.3 percent in February 2025, it bounced back with gains of 6.6 percent in January, 2.8 percent in March, and 6 percent in April. So far in May, it has added another 2.6 percent, though it remains down about 2 percent on a one-year basis. In a related corporate development, Nestle SA—the parent company of Nestle India—announced a minority investment in Drools Pet Food Private Limited, marking its first such move in India. While financial specifics of the deal were not disclosed, the transaction follows a $60 million funding round by Drools in 2023, which included backing from LVMH-supported private equity firm L Catterton. Drools will remain operationally independent post-investment, as per a statement released by the company. Nestle SA's entry into the Indian pet care segment comes at a time when the sector is witnessing rapid growth and increasing investor attention. Last week, Nestle India reported a standalone net profit of ₹ 885 crore for the quarter ended March 2025, registering a 5.2 percent year-on-year decline. However, revenue from operations rose 4.5 percent to ₹ 5,504 crore. Both top-line and bottom-line figures slightly beat market expectations. The company's EBITDA stood at ₹ 1,389 crore, reflecting a 3.9 percent growth from the same quarter last year. The EBITDA margin came in at 25.2 percent, slightly lower by 20 basis points year-on-year but still ahead of the 24.4 percent estimated by analysts. Margin pressures were primarily attributed to high cocoa prices. To reward shareholders, Nestle India also declared a final dividend of ₹ 10 per share for FY25. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
6 days ago
- Health
- Time of India
Daycare chemo centres in Karnataka's 16 districts to improve cancer care
Bengaluru: The govt will launch daycare chemotherapy centres in 16 districts to improve access to cancer treatment and reduce the burden on tertiary hospitals. The initiative aims to address the challenges faced by cancer patients, particularly those from rural areas. Health minister Dinesh Gundu Rao said: "Karnataka records approximately 70,000 new cancer cases annually. The most common cancers are breast (18%), cervical (14%), oral (12%), lung (8%) and colorectal (6%). Oral cancer incidence in the state stands at 12 cases per 1 lakh population, which is higher than the national average, while the incidence of breast cancer is 35 cases per 1 lakh women population." Statistics provided by the department revealed that 60% of cancer patients travel over 100km to access chemotherapy services in cities like Bengaluru, Hubballi and Mysuru. "We saw high dropout rates — 30% — due to cost and logistics of repeated visits," he said. According to the minister, the new centres will be set up under hub-and-spoke model, in which tertiary care hospitals will serve as hubs and district-level hospitals will act as spokes. In Karnataka, they will be set up through an MoU between tertiary care centres and district daycare chemotherapy centres (DCCCs). The hubs will handle complex procedures and diagnostics, while DCCCs will provide outpatient chemotherapy, palliative care, counselling and basic laboratory investigations. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 월 2만원으로 저소득 아이들의 한끼 선물하기 굿네이버스 더 알아보기 Undo "The centres are expected to reduce travel time for patients, bring down out-of-pocket expenses by an estimated 40% and improve treatment adherence by making services more accessible. For hospitals, it will decongest the burden on tertiary centres," he explained. Each DCCC will be staffed with a visiting medical oncologist, two trained nurses, physician, pharmacist and counsellor. Drug procurement will follow standardised protocols based on the essential medicines list issued by Suvarna Arogya Suraksha Trust (SAST). "The districts where DCCCs are being established are Bagalkot, Ballari, Bengaluru Urban/Rural, Ramanagara, Chitradurga, Dakshina Kannada, Davanagere, Dharwad, Haveri, Kolar, Mysuru, Tumkur, Udupi, Vijayanagara and Vijayapura," the minister added.
